**Table 1. Comparison of clinical, history, and demographic characteristics in the study patients**

|  |  |  |
| --- | --- | --- |
| **Parameter** | **Study group** | ***P* value** |
| **Basic anti-CAD + anxiolytic treatment (n = 30)** | **Basic anti-CAD treatment (n = 30)** |
| Age, Me [Q1; Q3], years | 60 [55.5; 65,5] | 62 [57; 68] | 0.166 |
| Time after revascularization, Me [Q1; Q3], full days | 7 [5; 9] | 6 [4; 8] | 0.467 |
| Gender, N (%) |
| Female | 12 (40.0) | 7 (23.3) | 0.267 |
| Male | 18 (60.0) | 23 (76.7) |
| History of myocardial infarction, N (%) |
| No | 21 (70.0) | 24 (80.0) | 0.552 |
| Yes | 9 (30.0) | 6 (20.0) |
| Heart failure, NYHA functional class, N (%) |
| I | 24 (80.0) | 17 (56.7) | 0.095 |
| II | 6 (20.0) | 13 (43.3) |
| Arterial hypertension, N (%) |
| No | 4 (13.3) | 6 (20.0) | 0.731 |
| Yes | 26 (86.7) | 24 (80.0) |
| Atherosclerosis of brachycephalic arteries, N (%) |
| No | 15 (50.0) | 16 (53.3) | 0.499 |
| Hemodynamically non-significant | 14 (46.7) | 11 (36.7) |
| Hemodynamically significant | 1 (3.3) | 3 (10.0) |
| Disorders of carbohydrate metabolism, N (%) |
| No | 26 (86.7) | 22 (73.3) | 0.333 |
| Type 2 diabetes mellitus | 4 (13.3) | 8 (26.7) |
| Revascularization indications, N (%) |
| Hemodynamically significant coronary atherosclerosis | 10 (33.3) | 6 (20.0) | 0.486 |
| Myocardial infarction | 16 (53.3) | 20 (66.7) |
| Acute coronary syndrome | 4 (13.3) | 4 (13.3) |

CAD, coronary artery disease

**Table 2. Regression of psychoautonomous abnormalities over time in the patients receiving basic anti-CAD treatment in combination with anxiolytic therapy**

|  |  |  |
| --- | --- | --- |
| **Parameter, Me [Q1; Q3]** | **Study period** | ***P* value (Fridman test)** |
| **In-patient** | **Out-patient** |
| **Day 1** | **Days 5 to 6** | **Days 10 to 14** |  | **Day 30** | **Days 45 to 60** |
| STAI-S, scores | 42 [40; 46] | 39 [37; 42] | 35 [32; 37] | 35 [32; 37] | 36 [33; 39] | < 0.001 |
| STAI-T, scores | 45 [41; 48] | 41 [38; 44] | 39 [33; 42] | 35 [32; 41] | 33 [32; 37] | < 0.001 |
| HADS-A, scores | 7 [4; 12] | 1 [0; 4] | 1 [0; 4] | 1 [0; 3] | 1 [1; 2] | < 0.001 |
| ESS, scores | 6 [5; 8] | 4 [3; 6] | 3 [1; 4] | 2 [1; 3] | 2 [1; 3] | < 0.001 |
| PSQI, scores | 8 [6; 12] | 5 [2; 7] | 3 [1; 5] | 4 [3; 5] | 2 [2; 4] | < 0.001 |
| DAA, scores | 23 [12; 33] | 7 [5; 20] | 5 [0; 11] | 10 [5; 17] | 5 [0; 10] | < 0.001 |
| KVI | -3 [-9; -5] | -4 [-11; -3] | -12 [-20; -5] | -11 [-21; -5] | -13 [-19; -7] | < 0.001 |
| MVCI | 1.17 [1.07; 1.27] | 1.1 [1.01; 1.16] | 1.02 [0.97; 1.09] | 1.07 [1; 1.13] | 1.04 [0.99; 1.07] | < 0.001 |
| Q | 4.6 [4.2; 4.8] | 4.2 [3.5; 4.7] | 4 [3.6; 4.1] | 4.1 [3.8; 4.5] | 3.9 [3.7; 4.3] | 0.005 |
| SDNN, ms | 73 [61; 89] | 84 [62; 101] | 88 [71; 110] | 96 [67; 122] | 113 [81; 132] | < 0.001 |
| pNN50, % | 1 [0; 3] | 1 [0; 4] | 3 [1; 10] | 3 [1; 9] | 4 [2; 10] | < 0.001 |
| RMSSD, ms | 20 [13; 26] | 19 [16; 26] | 25 [22; 33] | 27 [22; 37] | 30 [23; 39] | < 0.001 |
| SDNNidx, ms | 41 [31; 50] | 42 [32; 52] | 50 [41; 57] | 57 [41; 57] | 62 [48; 73] | < 0.001 |
| SDANN, ms | 51 [43; 68] | 72 [44; 82] | 62 [46; 81] | 67 [46; 97] | 79 [52; 106] | 0.006 |
| VLF, ms2 | 1392 [728; 2083] | 1110 [613; 1992] | 1921 [1266; 2492] | 2081 [1286; 2726] | 2185 [1504; 2971] | < 0.001 |
| LF, ms2 | 430 [129; 676] | 364 [126; 522] | 611 [349; 864] | 618 [390; 954] | 649 [345; 924] | < 0.001 |
| HF, ms2 | 108 [34; 142] | 98 [50; 149] | 139 [109; 320] | 149 [119; 207] | 177 [134; 244] | < 0.001 |

DAA, detection of autonomous abnormalities inventory; ESS, Epworth daytime sleepiness scale; HADS-A, Hospital Anxiety and Depression scale, subscale for anxiety; KVI, Kerdo vegetative index; MVCI, minute volume of circulation index; PSQI, Pittsburgh sleep quality inventory; Q, Hildebrandt coefficient; STAI-S, state anxiety by State and Trait Anxiety Inventory; STAI-T, trait anxiety by State and Trait Anxiety Inventory

**Table 3. Changes of psychoautonomous abnormalities over time in the patients receiving only basic treatment for coronary artery disease**

|  |  |  |
| --- | --- | --- |
| **Parameter, Me [Q1; Q3]** | **Study period** | ***P* value (Fridman test)** |
| **In-patient** | **Out-patient** |
| **Day 1** | **Days 5 to 6** | **Days 10 to 14** |  | **Day 30** | **Days 45 to 60** |
| STAI-S, scores | 42 [36; 43] | 40 [35; 43] | 40 [36; 45] | 41 [35; 43] | 40 [35; 43] | 0.062 |
| STAI-T, scores | 42 [40; 46] | 40 [38; 44] | 41 [39; 42] | 39 [35; 43] | 40 [35; 42] | 0.005 |
| HADS-A, scores | 7 [4; 9] | 7 [5; 10] | 8 [5; 10] | 6 [4; 8] | 6 [4; 7] | < 0.001 |
| ESS, scores | 8 [6; 10] | 8 [6; 10] | 6 [4; 9] | 7 [4; 9] | 7 [4; 9] | 0.06 |
| PSQI, scores | 6 [3; 9] | 6 [4; 9] | 6 [4; 8] | 5 [4; 8] | 5 [4; 7] | 0.849 |
| DAA, scores | 16 [9; 30] | 16 [8; 28] | 16 [5; 28] | 16 [7; 23] | 17 [10; 28] | 0.058 |
| KVI | -7 [15; 3] | -5 [-11; 0] | -5 [-11; -1] | -6 [-8; -3] | 2 [-7; 4] | 0.013 |
| MVCI | 1.13 [1.06; 1.18] | 1.11 [1.06; 1.19] | 1.16 [1.1; 1.18] | 1.15 [1.09; 1.17] | 1.19 [1.13; 1.21] | 0.002 |
| Q | 4.4 [4.0; 4.6] | 4.3 [4.0; 4.6] | 4 [4.2; 4.6] | 4.5 [4.2; 4.6] | 4.4 [4.2; 4.6] | 0.5 |
| SDNN, ms | 70 [44; 95] | 66 [50; 82] | 72 [50; 85] | 65 [48; 92] | 59 [48; 80] | 0.077 |
| pNN50, % | 2 [1; 5] | 2 [1; 5] | 4 [1; 5] | 2 [0; 3] | 1 [1; 4] | 0.197 |
| RMSSD, ms | 23 [16; 35] | 22 [15; 31] | 22 [16; 29] | 22 [16; 31] | 22 [14; 29] | 0.629 |
| SDNNidx, ms | 38 [31; 44] | 34 [27; 44] | 38 [33; 48] | 34 [18; 46] | 34 [24; 46] | 0.111 |
| SDANN, ms | 47 [28; 84] | 40 [26; 62] | 44 [36; 66] | 47 [32; 54] | 47 [34; 54] | 0.304 |
| VLF, ms2 | 990 [864; 1114] | 710 [626; 926] | 786 [644; 1010] | 989 [625; 1239] | 1082 [748; 1316] | 0.015 |
| LF, ms2 | 413 [304; 805] | 374 [178; 460] | 296 [156; 418] | 320 [174; 677] | 418 [187; 592] | 0.027 |
| HF, ms2 | 89 [69; 186] | 78 [42; 113] | 82 [50; 148] | 157 [89; 189] | 174 [78; 229] | 0.002 |

DAA, detection of autonomous abnormalities inventory; ESS, Epworth daytime sleepiness scale; HADS-A, Hospital Anxiety and Depression scale, subscale for anxiety; KVI, Kerdo vegetative index; MVCI, minute volume of circulation index; PSQI, Pittsburgh sleep quality inventory; Q, Hildebrandt coefficient; STAI-S, state anxiety by State and Trait Anxiety Inventory; STAI-T, trait anxiety by State and Trait Anxiety Inventory

**Table 4. The significant levels (P values) for the difference in the psychoautonomous abnormality parameters during the study periods between the groups of patients receiving only basic treatment for coronary artery disease (CAD) (n = 30) and patients receiving an anxiolytic in addition to basic anti-CAD treatment (n = 30)**

|  |  |
| --- | --- |
| **Parameter, Me [Q1; Q3]** | **Study period** |
| **In-patient** | **Out-patient** |
| **Day 1** | **Days 5 to 6** | **Days 10 to 14** |  | **Day 30** | **Days 45 to 60** |
| STAI-S | 0.155 | 0.367 | < 0.001\* | 0.003\* | < 0.001\* |
| STAI-T | 0.467 | 0.806 | 0.021\* | 0.040\* | < 0.001\* |
| HADS-A | 0.964 | < 0.001\* | < 0.001\* | < 0.001\* | < 0.001\* |
| ESS | 0.546 | 0.010\* | < 0.001\* | < 0.001\* | < 0.001\* |
| PSQI | 0.079 | 0.046\* | 0.001\* | 0.027\* | < 0.001\* |
| DAA | 0.304 | 0.079 | 0.002\* | 0.151 | < 0.001\* |
| KVI | 0.062 | 0.680 | 0.020\* | 0.042\* | < 0.001\* |
| MVCI | 0.151 | 0.324 | < 0.001\* | 0.005\* | < 0.001\* |
| Q | 0.164 | 0.376 | < 0.001\* | 0.009\* | < 0.001\* |
| SDNN | 0.469 | 0.054 | 0.040\* | 0.002\* | < 0.001\* |
| pNN50 | 0.052 | 0.269 | 0.517 | 0.050 | 0.010\* |
| RMSSD | 0.061 | 0.555 | 0.041\* | 0.067 | 0.003\* |
| SDNNidx | 0.424 | 0.206 | 0.007\* | < 0.001\* | < 0.001\* |
| SDANN | 0.684 | 0.018\* | 0.067 | 0.003\* | < 0.001\* |
| VLF | 0.132 | 0.056 | < 0.001\* | < 0.001\* | < 0.001\* |
| LF | 0.280 | 0.987 | 0.010\* | 0.064 | 0.053 |
| HF | 0.304 | 0.692 | 0.020\* | 0.409 | 0.352 |

DAA, detection of autonomous abnormalities inventory; ESS, Epworth daytime sleepiness scale; HADS-A, Hospital Anxiety and Depression scale, subscale for anxiety; KVI, Kerdo vegetative index; MVCI, minute volume of circulation index; PSQI, Pittsburgh sleep quality inventory; Q, Hildebrandt coefficient; STAI-S, state anxiety by State and Trait Anxiety Inventory; STAI-T, trait anxiety by State and Trait Anxiety Inventory

\* The difference between the study groups is significant